{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:28:56Z","timestamp":1791851336164,"version":"4.3.4"},"reference-count":22,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>Empagliflozin was found to decrease mortality in patients with type 2 diabetes mellitus (T2DM) and a prior cardiovascular disease (CVD) event.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives:<\/jats:title>\n                  <jats:p>To establish whether these benefits can be replicated in a real-world setting, should be expected with the use of dapagliflozin, and apply to T2DM patients at low risk of CVD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design:<\/jats:title>\n                  <jats:p>General practice, population-based, retrospective cohort study (January 2013 to September 2015).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting:<\/jats:title>\n                  <jats:p>The Health Improvement Network database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants:<\/jats:title>\n                  <jats:p>A total of 22,124 T2DM patients (4444 exposed to dapagliflozin; 17,680 unexposed T2DM patients) matched for age, sex, body mass index, T2DM duration, and smoking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures:<\/jats:title>\n                  <jats:p>The primary outcome was all-cause mortality (high and low risk for CVD) in the total study population, expressed as the adjusted incidence rate ratio (aIRR) with 95% confidence intervals (CIs). As a secondary analysis in the low-risk population, all-cause mortality and incident CVD were considered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Patients with T2DM exposed to dapagliflozin were significantly less likely to die of any cause (aIRR: 0.50; 95% CI: 0.33 to 0.75; P = 0.001). Similarly, in low-risk patients, death from any cause was significantly lower in the cohort exposed to dapagliflozin (aIRR: 0.44; 95% CI: 0.25 to 0.78; P = 0.002). The difference in the risk of incident CVD did not reach statistical significance between groups in low-risk patients (aIRR: 0.89; 95% CI: 0.61 to 1.31; P = 0.546).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>Patients with T2DM who were exposed to dapagliflozin had a lower risk of death from any cause irrespective of baseline CVD status.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2016-3446","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T15:10:19Z","timestamp":1492614619000},"page":"1719-1725","source":"Crossref","is-referenced-by-count":66,"title":["All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database"],"prefix":"10.1210","volume":"102","author":[{"given":"Konstantinos A.","family":"Toulis","sequence":"first","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, United Kingdom"},{"name":"Department of Endocrinology, 424 General Military Hospital, Thessaloniki 56429, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Willis","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Marshall","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balachadran","family":"Kumarendran","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Gokhale","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Diabetes Department, University Hospitals Birmingham, NHS Foundation Trust, Birmingham B15 2TH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Neil","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar Keung","family":"Cheng","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Narendran","sequence":"additional","affiliation":[{"name":"Institute of Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, United Kingdom"},{"name":"Diabetes Department, University Hospitals Birmingham, NHS Foundation Trust, Birmingham B15 2TH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasim","family":"Hanif","sequence":"additional","affiliation":[{"name":"Diabetes Department, University Hospitals Birmingham, NHS Foundation Trust, Birmingham B15 2TH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnarajah","family":"Nirantharakumar","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, United Kingdom"},{"name":"Diabetes Department, University Hospitals Birmingham, NHS Foundation Trust, Birmingham B15 2TH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,2,20]]},"reference":[{"issue":"8","key":"2020071621582500600_B1","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.2337\/dc12-1513","article-title":"All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database","volume":"36","author":"Taylor","year":"2013","journal-title":"Diabetes Care"},{"key":"2020071621582500600_B2","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"2020071621582500600_B3"},{"key":"2020071621582500600_B4","doi-asserted-by":"crossref","first-page":"b4731","DOI":"10.1136\/bmj.b4731","article-title":"Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database","volume":"339","author":"Tzoulaki","year":"2009","journal-title":"BMJ"},{"key":"2020071621582500600_B5"},{"issue":"12","key":"2020071621582500600_B6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S2213-8587(15)00426-X","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Ceriello","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020071621582500600_B7"},{"issue":"12","key":"2020071621582500600_B8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S2213-8587(15)00427-1","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Gilbert","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2020071621582500600_B9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","article-title":"EMPA-REG - the \u201cdiuretic hypothesis\u201d","volume":"30","author":"McMurray","year":"2016","journal-title":"J Diabetes Complications"},{"issue":"12","key":"2020071621582500600_B10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2020071621582500600_B11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diabet.2015.12.005","article-title":"Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis","volume":"42","author":"Scheen","year":"2016","journal-title":"Diabetes Metab"},{"key":"2020071621582500600_B12"},{"issue":"2","key":"2020071621582500600_B13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/dom.12418","article-title":"Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study","volume":"17","author":"Sha","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2020071621582500600_B14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/pds.1686","article-title":"Validation of death and suicide recording on the THIN UK primary care database","volume":"18","author":"Hall","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2020071621582500600_B15","first-page":"251","article-title":"Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates","volume":"19","author":"Blak","year":"2011","journal-title":"Inform Prim Care"},{"issue":"5","key":"2020071621582500600_B16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2020071621582500600_B17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2407-4-94","article-title":"An electronic application for rapidly calculating Charlson comorbidity score","volume":"4","author":"Hall","year":"2004","journal-title":"BMC Cancer"},{"key":"2020071621582500600_B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2296-11-1","article-title":"Adaptation and validation of the Charlson Index for Read\/OXMIS coded databases","volume":"11","author":"Khan","year":"2010","journal-title":"BMC Fam Pract"},{"issue":"3","key":"2020071621582500600_B19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"5","key":"2020071621582500600_B20","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1210\/jc.2014-3481","article-title":"Bisphosphonates and glucose homeostasis: a population-based, retrospective cohort study","volume":"100","author":"Toulis","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2020071621582500600_B21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2020071621582500600_B22","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jacc.2004.02.001","article-title":"Evidence-based guidelines for cardiovascular disease prevention in women","volume":"43","author":"Mosca","year":"2004","journal-title":"J Am Coll Cardiol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/5\/1719\/16629983\/jc.2016-3446.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/5\/1719\/16629983\/jc.2016-3446.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T09:40:32Z","timestamp":1594978832000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/102\/5\/1719\/3038070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,20]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2016-3446","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,1]]},"published":{"date-parts":[[2017,2,20]]}}}